Press Releases May 21, 2026 06:00 AM

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to engage investors at multiple upcoming conferences to showcase diagnostic innovations

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
BDSX

Biodesix, Inc., a diagnostics solutions company, announced its participation in three forthcoming investor conferences where its leadership will conduct presentations and meetings, highlighting its diagnostic technologies for lung disease and development services for biopharmaceutical companies.

Biodesix to Participate in Upcoming Investor Conferences
BDSX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Biodesix leadership to participate in Craig-Hallum, William Blair, and TD Cowen annual investor conferences in May and June 2026.
  • The company focuses on diagnostic tests like Nodify Lung® and IQLung® that support personalized care for lung disease patients.
  • Biodesix also offers development services to biopharmaceutical and research institutions, enhancing diagnostic and therapeutic developments.

LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences:

Craig-Hallum 23rd Annual Institutional Investor Conference
1x1 meetings only
Date: Thursday, May 28, 2026
Location: Minneapolis, MN

William Blair 46th Annual Growth Stock Conference
Presentation and 1x1 meetings
Presentation Date and Time: Wednesday, June 3, 2026 at 2:00 PM CT
Location: Chicago, IL

TD Cowen Annual Tools/Dx Revolution
1x1 meetings only
Date: Wednesday, June 24, 2026
Location: Dana Point, CA

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix's website at Biodesix.com.

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843


Risks

  • Investor conferences typically do not guarantee immediate financial or operational impacts, leading to potential market indifference.
  • Future financial benefits depend on successful commercialization and adoption of diagnostic tests amidst competitive healthcare and biotech sectors.
  • Ongoing dependency on biopharmaceutical partners introduces risks associated with collaboration outcomes and regulatory approvals.

More from Press Releases

Tims China Announces First Quarter 2026 Financial Results Jun 9, 2026 Nathan's Famous, Inc. Reports Year End and Fourth Quarter Results Jun 9, 2026 Parsons Secures a Total of $218 Million on AFRL GARDEM Contracts Jun 9, 2026 Tims China Announces Appointment of Mr. Kwok Wah Cheung as Chief Executive Officer and Issuance of Additional Senior Secured Convertible Notes Jun 9, 2026 Canadian Entrepreneurship Declines, Challenges Build As Companies Fall Behind with Lenders Jun 9, 2026